Research Overview of Alrista SR 150 mg
Alrista SR 150 mg Macleods is a sustained-release pharmaceutical preparation manufactured under strict quality control protocols for laboratory research applications. This formulation demonstrates extended-release characteristics through specialized tablet matrix technology, making it valuable for pharmacokinetic studies and dissolution research. The 150 mg strength provides standardised dosing parameters for controlled analytical investigations. Researchers examining Stroid UK Shop often require sustained-release preparations to study prolonged drug delivery mechanisms and bioavailability profiles in laboratory settings.
Laboratory Research Applications
This sustained-release formulation serves multiple research purposes in pharmaceutical laboratories. Scientists investigating drug dissolution kinetics can analyse the controlled-release properties of this tablet matrix system. The formulation’s extended-release profile makes it suitable for studies examining plasma concentration curves and pharmacokinetic modelling. Researchers in the other drugs category frequently utilise such preparations for comparative bioavailability studies. The tablet’s consistent manufacturing ensures reproducible results across experimental protocols, supporting research into therapeutic equivalence and generic drug development.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Content | 150 mg per tablet |
| Formulation Type | Sustained-release tablet |
| Manufacturer | Macleods Pharmaceuticals |
| Release Profile | Extended-release matrix |
| Storage Conditions | Room temperature, dry environment |
| Analytical Standards | USP/EP compliant testing |
The manufacturing process follows international pharmaceutical standards, ensuring batch-to-batch consistency crucial for research applications. Quality control testing verifies content uniformity, dissolution profiles, and stability parameters. Researchers studying drug delivery systems alongside selective androgen receptor modulators or research peptides benefit from this formulation’s reliable performance characteristics. The sustained-release technology provides controlled drug release over extended periods, facilitating studies of prolonged therapeutic effects and reducing dosing frequency in experimental models.
Research Compliance Statement
Alrista SR 150 mg Macleods is supplied exclusively for legitimate scientific research and analytical purposes in accredited laboratory facilities. This product is not intended for human consumption, therapeutic use, or any application outside controlled research environments. All research activities must comply with institutional ethics guidelines and relevant regulatory frameworks. Proper laboratory safety protocols should be observed during handling and analysis. This pharmaceutical preparation supports academic research, drug development studies, and analytical method validation in qualified research institutions.
